Trial
NCT03038477
A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Colorado, Denver
Collaborators
AstraZeneca
Condition
Pancreatic Cancer
Intervention
Durvalumab
Why stopped
Cancelled by PI
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-09-14